Novo SVP on NASH collaboration with Gilead: "It's the first step"

Novo Nordisk and US-based Gilead Sciences have joined forces in a new clinical trial with the fatty liver disease NASH. Although the partnership only entails one study for now, it could kick off more collaborations in the field, says Novo's Head of Global Drug Discovery, who also anticipates similar agreements with other actors.

Photo: Novo Nordisk

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles